Investor Ideas #Potcasts
578, #Cannabis News and #Stocks on the Move; Interview with CEO of Albert Labs- improving patient access to #psychedelic
assisted #therapies
Delta, Kelowna, BC, June 22, 2021 (Investorideas.com Newswire) www.Investorideas.com,
a global news source covering leading sectors including marijuana and hemp
stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/062221-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/News/2021/cannabis-potcasts/06221Interview-Albert-Labs.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast Investorideas interviews Dr. Michael Raymont, CEO of Albert
Labs, a laboratory based, clinical research and drug development enterprise,
focused on improving patient access to psychedelic assisted therapies through
accelerated regulatory approval pathways, where we discussed the companies
unique approach through Real World Evidence studies, the psychedelic landscape
in the EU and UK as well as expectations around how the medical side of
psychedelics will continue to develop.
Dr.
Raymont’s career has spanned leadership roles in venture capital, agricultural
and healthcare investment, tech company leadership and senior Government
service, where he ran the National Research Council (NRC), Canada’s largest
R&D organization. With a background
in both science and business, Dr. Raymont has advised corporations and
governments, worked extensively internationally, and has sat on the boards of
over 50 public and private companies.
The company recently
sent its
application for listing on the Canadian Securities
Exchange (“CSE”). The Listing Statement submission will initiate a consulting
phase by the CSE with the Company in preparation for subsequent listing of the
common shares in the capital of the resulting issuer Albert Labs, subject to
satisfying requirements of the CSE. While there can be no guarantee the Common
Shares will be successfully listed on the CSE, Albert Labs is working towards
the listing execution of definitive documents and closing with respect to the
RTO definitive agreement dated March 5th.
Chand Jagpal, the Chief Operations
Officer of Albert Labs, stated “The much anticipated submission of the listing
statement represents a significant milestone for Albert Labs. We’re excited to
move towards our goal of becoming a public company to attract growth capital
and enable Albert Labs to continue towards its goal of being a worldwide leader
and provide accelerated access to psychedelics medicines and therapy”
When asked what separates Albert
Labs from other competitors in the psychedelic space, Dr. Michael Raymont
commented, “Albert labs is differentiated from our competitors by a unique
strategy, and that unique strategy uses an asset light model and ,very
important for investors, we are really focussed on speed to market. Speed to
market means speed to revenues, and speed to revenues means faster returns for
investors.”
“So how are we bringing these
products to market? We’re using an approach that is Real World Evidence
studies. Real World Evidence studies differ from clinical trials. Here’s the
essential thing for investors, the difference, apart from the actual pathway
towards regulatory approval, is the fact that Real World Evidence trials can be
run and approved in a matter of months for a few million dollars rather than a
matter of many years in most cases for clinical trial approved drugs and the
common number today for clinical blockbuster drugs is roughly a half a billion
dollars. So it’s risk mitigated, it’s fast to market, faster to revenues and it
is safe,” Raymont continued.
Albert Labs, unlike some of its
competitors today, is also much more focussed when it comes to the specific
ailments they look to address through psychedelics as Raymont mentioned, “Real
World Evidence trials tend to focus on a pretty specific outcome and a pretty
specific problem. So in our case at Albert Labs, we are focussed on treating
anxiety in cancer patients, we are not trying to treat general anxiety. We may
be able to treat other anxiety related situations beyond cancer but we would
have to go through other trials in order to have the medicine used for
something else.”
Dr. Michael Raymont went on to
discuss the benefits of focussing on the UK and EU initially, growing interest
from physicians and the mainstream medical community, which specific
psychedelic compounds the company aims to work with initially and in the future
of psychedelics when it comes to the difference between the medicinally
focussed segment of the industry and the segment pushing for more of a
recreational model.
To find out more information about
Albert Labs click here.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on
iTunes ( Apple Podcasts) , Audible ,
Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Play Music and most audio platforms
available.
Potcasts is now
a certified word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
Investors can trade these stocks and
other ideas on our site using our list
of top stock trading apps
including Robinhood , Acorn, Stash and
others.
About Investorideas.com -
News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research , guest posts and
original articles and podcasts in
leading stock sectors. Learn about
investing in stocks and get investor
ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy, gaming and more. Investor Idea’s original branded content includes
podcasts and columns : Crypto Corner , Play by Play
sports and stock news , Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks
Podcast and the AI Eye
Podcast.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile
App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact
Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment